The financing round, with a total volume of approximately €26 million ($29 million), was led by Blueyard Capital and Sprind. Bayern Kapital, Marius Nacht Group, Andrej Henkler, and several industry-experienced business angels also invested in CPTx. The startup plans to invest the funds in the further development of its antiviral platform technology and in expanding its team.
CPTx, short for Composite Programmable Therapeutics, was founded in 2021 as a spin-off of the Technical University of Munich. Biotech-Company develops a new Platform technology, which combines so-called DNA nanofabrication with synthetic biology. This will enable the creation of customized objects in scalable quantities that can perform various functions in drug development. In this process, a target object is designed and its 3D shape and functionality are encoded into DNA strands. These strands are then manufactured chemically or biotechnologically and assembled through thermal annealing. Combined with other functions, the CPTx platform is intended to offer new possibilities for antiviral therapeutics, gene transfer, and vaccine development.
Hendrik Dietz, CEO and founder of CPTx, comments on the financing:
"We are very pleased that a consortium of industry-experienced investors has recognized the immense potential of our platform technology. This enables us to complete the preclinical development phase and explore further fields of application."
And Monika Steger, Managing Director of Bayern Kapital, says:
"Given our experiences with the COVID pandemic, but also with the annual flu epidemics, we know how important it is to have options for treating viral diseases. CPTx is the result of years of intensive research, some of which have made new possibilities such as the use of DNA nanofabrication on a scalable, cost-effective scale possible. The team's academic and entrepreneurial expertise is immense, and this current funding is another example of how Bayern Kapital supports innovative spin-off projects from Bavarian universities based on outstanding technologies, even in their early stages. We see great potential for CPTx to become a leading company in the field of nanotechnology."
